We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
BioMed X Starts New Schizophrenia Research Program with Boehringer Ingelheim
Product News

BioMed X Starts New Schizophrenia Research Program with Boehringer Ingelheim

BioMed X Starts New Schizophrenia Research Program with Boehringer Ingelheim
Product News

BioMed X Starts New Schizophrenia Research Program with Boehringer Ingelheim


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "BioMed X Starts New Schizophrenia Research Program with Boehringer Ingelheim"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

BioMed X has announced the start of a new joint research group in collaboration with Boehringer Ingelheim at the BioMed X Innovation Center in Heidelberg. The aim of the new research project is to investigate myelination deficits of the adolescent brain in connection with the development of schizophrenia.

Psychiatric disorders such as schizophrenia emerge as consequence of abnormal brain development and maturation. During adolescence, the brain is reorganized for mature function by processes such as cortical myelination, dendritic arborization, synaptic pruning, and circuit plasticity. Particularly in schizophrenia, there is evidence that genetic, epigenetic and environmental factors negatively affect the balanced functional maturation during adolescence and cumulatively increase the risk for developing symptoms.

The new group supported by Boehringer Ingelheim will specifically investigate the myelination deficits, which have been observed in the brains of schizophrenia patients. The approach includes the development of in vitro and in vivo platforms to study oligodendrocyte development and myelination. The goal of the project is to identify novel extrinsic (neuronal) and intrinsic (oligodendrocytic) factors affecting myelination as potential new targets for the prevention of schizophrenia in high-risk individuals.


Advertisement